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Translational genomics is both the title and mission of this new
journal. Translational research has a long history of practice that was
formalized by the creation of the U.S. NIH National Center for Transla-
tional Research (Collins, 2011) and the UK's Medical Research Council
program in Translational Research (http://tinyurl.com/owmvp4o).
Governments throughout the world are funding research programs
and centers (e.g., (Daiming et al., 2012)) through grant funding
mechanisms such as EU's H2020 (Andersson, 2012). The goals of
these initiatives are to decrease failure rates, expenses, and timelines
for drug and evidence-based product and solution development. Inore, Nestlé Institute of Health
Lausanne, Switzerland.
This is an open access article under thparallel with these government-funded programs, the U.S. Food
and Drug Administration's Critical Path Initiative (Woodcock and
Woosley, 2008), the European Union's InnovativeMedicine Initiative
(Goldman, 2012), and the European Advanced Translational Research
Infrastructure inMedicine (EATRIS— http://www.eatris.eu/)were initi-
ated to foster public–private partnerships to enhance translation of
basic biomedical research into patient- and consumer-end products
and solutions. Not long ago, “translational”was an acronym for applied
research or development (i.e. the “D” in “R&D”), an anathema to many
investigators conducting basic research. However, recent scientiﬁc,
technological and societal developments are now causing a re-
assessment of the negative connotation of “applied” and “develop-
ment” and the – in our view misleading – idea that “translational”
and “basic” are either/or activities: translational research simply
seeks to combine the best science with applications in real time fore CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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from “applied” science, we propose here to challenge and leverage
basic science for its relevance to human health and societal beneﬁts.
This more recent approach and emerging scientiﬁc attitude root in
four developments that we will outline hereunder: (1) evidence-based
solutions; (2) “big data”; (3) consumer/patient empowerment; and
(4) system thinking.
2. Development 1: The increasing need for evidenced-based
solutions
The increasing prevalence of complex, age-related chronic diseases
in developing and emerging economies is intensifying scientiﬁc, ethical
and economic calls to improve the healthcare system (Callahan, 2013)
and act on related health disparities (Dankwa-Mullan et al., 2010).
Governments, companies, and philanthropic organizations recognize
these realities and are now challenging investigators in “basic” research
ﬁelds to translate their ﬁndings to actionable knowledge or products
(Hobin et al., 2012). The burden is intense for the genomics ﬁeld,
which (over)promised rapid solutions to disease from leveraging data
from the Human Genome (Consortium, 2001; Venter et al., 2001),
HapMap (International HapMap Consortium, 2003), and related pro-
jects on human genetic diversity (Li et al., 2008; Siva, 2008).
3. Development 2: High-throughput laboratory and clinical data
generation
The second development reinforcing the concept that basic research
can be translatable is the ongoing evolution in the ability to quantify
physiologies and genetic makeups of large numbers of study partici-
pants and patients using omics-based and imaging technologies.
“Omics” analysis is meant to suggest a comprehensive analysis of mole-
cules (i.e., genes/transcripts/proteins/lipids/metabolites) but in reality
means as many molecules as the technology allows, with ranges of
~10s of chemically similar molecules (e.g., water-soluble organic
micronutrients) to millions and soon billions of DNA bases.
In many cases, omic analysis is done with untargeted methods in a
high-throughput screen (e.g. NMR-based metabonomics, or MS-based
proteomics), which is then followed by more targeted and hence
more sensitive methods focusing on a subset of molecules. Targeted
quantiﬁcation requires speciﬁc method development, in contrast to
the generic screening methods. Such hypothesis-limited (Editorial,
1999) approaches differ from assessing a speciﬁc research question by
means of measuring selected molecular readouts but promise to pro-
videmore comprehensive understanding of biological processes thanks
to conceptually unbiased analysis (Kaput and Morine, 2012). These
omics sciences have evolved over the last few decades and are prime
examples of how technology has transformed and driven biomedical
and other areas of biology research.
4. Development 3: Self-quantiﬁcation and consumer empowerment
Knowledge-bases and clinical/diagnostic translations are outcomes
of omics research, which essentially provide the dictionaries of compo-
nents of human life. In almost all cases however, omics databases pro-
vide information about population averages or ranges for a molecule
in a bioﬂuid (e.g., Human Metabolome Database — http://www.hmdb.
ca). In many such cases, these ranges are speciﬁc to the tested popula-
tion since not all (or even many) ancestral genetic makeups have been
sampled. Public health recommendations and clinical care are often
based on the information captured in these databases but the information
has to be individually adapted to the patient/consumer/person. Omics
data obtained from analyzing one person has demonstrated the long-
known facts of biochemical and genetic individuality (Williams, 1956).
The growing self-quantiﬁcation movement and several citizen sci-
ence research projects are disrupting the population average databasemodel since individuals are now sharing n-of-1 data, including genomic
information. This open genome and personal data access movement
started with the Personal Genome Project at Harvard, which sequenced
and allowed access to the genomes of 10 individuals (Church, 2005;
Lunshof et al., 2010). An individual can obtain his/her genetic data
from commercial companies (such as 23andme, FamilyTreeDNA).
While the U.S. FDA has restricted these and other companies from pro-
viding associations to trait, phenotype, or disease (Green and Farahany,
2014), no restrictions were placed on the right of individuals to own
their personal data (Angrist, 2014). Hence, individuals can and do
share their data. OpenSNP (https://opensnp.org/) has about 2000 par-
ticipants (accessed 18 April 2014)whohave uploaded their genetic var-
iation data, phenotypes, and traits with an option to allow their data to
be downloaded by others for computational analysis. Associating indi-
vidual genetic variants with complex phenotypes is less than robust
(Ransohoff and Khoury, 2010) mitigating present-day concerns about
the potential for discriminatory use of genomic data, However, ongoing
research increasingly associates patterns of gene variants with suscepti-
bilities to diseases and traits and privacy concerns are likely justiﬁed.
Access to individual genomic data holds great promise for making
these associations. However, among the limiting factors for analyzing
genetic data and outcomes is the lack of reliable and standardized die-
tary and lifestyle data, plus the missing access to personal omics data.
A person's “molecular” phenotype is deﬁned not only by classical mea-
sures such as body weight, blood pressure and clinical blood chemistry
parameters, but also by their changing metabolites, transcripts, and
proteins. Web-enabled research tools that capture, manage, store, and
retrieve these personal molecular phenotype and lifestyle data are un-
available to the research community (Stumbo et al., 2010). NuGO, the
former EU framework six-funded Nutrigenomics Organization and now
scientiﬁc association (http://www.nugo.org), has launched the nutrition
researcher cohort (NRC — http://www.nugo.org/nrc and (van Ommen,
2013)), an initiative to develop anopen access cohortwhere each individ-
ual provides and owns her/his own health data that can be analyzed by
the individual (e.g., (Chen et al., 2012)). However, the true strength of
NRC will come from aggregating individual data with data from other
members of the cohort (Monteiro et al., 2014;Nikles et al., 2011) to devel-
op more in depth understanding of health phenotypes.
The smartphone revolution is being used by NRC and other initia-
tives since at least 500 apps (from http://quantiﬁedself.com/guide/ —
17 April 2014) exist to monitor all aspects of life including dietary in-
takes, sleep, moods, activity and physiological measures such as heart
rate variability (Flatt and Esco, 2013), stress, blood glucose, or cholester-
ol levels (Oncescu et al., 2014). Healthcare (Boulos et al., 2011) and
research activities may be transformed by the self-quantiﬁcationmove-
ment if the diet and lifestyle data captured by apps and devices is of
high quality and accuracy (Young et al., 2014). Data harmonization
(Lynn et al., 2010; van Ommen et al., 2010) will also be essential for
enabling system approaches to analysis of high dimensional data.
5. Development 4: System thinking and analysis
Modern biomedical research relies on very detailed mapping of bio-
chemical reactions and interactions (e.g., http://web.expasy.org/cgi-
bin/pathways/show_thumbnails.pl) that were generated largely from
reductionist methods that examined each reaction either in isolation
from other reactions or in limited biochemical contexts. While time-
tested experimental methods continue to generate ever-ﬁner details
of these processes, the simple visual ﬁgures of biochemical transforma-
tions can give “the illusion of explanatory depth” (Rozenblit and Keil,
2002). Despite their utility for mechanistic research, biological out-
comes can usually not be predicted from this knowledge base. Metabo-
lism and its regulation form a complex interacting set of processes that
change over time and in different environments.
System thinking and computationalmethods are nowbeing increas-
ingly used to help analyze and visualize biological systems such as
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well as response to vaccines (Afacan et al., 2012; MacLellan et al.,
2012; Poland et al., 2013; Slikker et al., 2007; van Ommen et al., 2008;
Zhao et al., 2012). Modern system concepts (e.g., Hood et al., 2004)
call for (i) high-throughput, quantitativemeasures of the genome, tran-
scriptome, proteome, metabolome, and/or cytome levels; (ii) over time
in homeostatic and challenged states, allowingmetabolic ﬂux analyses;
(iii) integration and (meta-) analyses of data with computational net-
work biology methods; and (iv) modeling to unravel mechanistic
relationships of the biological processes.
Many of these system biology deﬁnitions and experimental ap-
proaches, however, miss the crucial inclusion of measuring environ-
mental factors such as diet, psycho-social factors, physical activity, and
other lifestyle factors, each of which may inﬂuence expression of
genes, levels of proteins and metabolites (Kussmann et al., 2013). The
human body is not a closed system as demonstrated by changes in
blood concentrations of one-carbon metabolites and cofactors as a con-
sequence of seasonal differences in nutrient availability (Dominguez-
Salas et al., 2013).
Network-based methods describing health, subsystems of physiolog-
ical processes, and pathological states (Mayer et al., 2013; Morine and
Priami, 2013) provide the foundation for developing these systems-
based models based on analysis of high-quality, high-dimensional
genomic, proteomic, and/or metabolomic data with appropriate ﬁltering
fromprospective and intervention studies. The conceptual pipeline (from
(Kaput et al., 2014)) includes:
• Computational deﬁnition of systemnetworks and sub-networks asso-
ciated with health and pathologies and the underlying pathways,
functional attributes, and mechanisms.
• Deﬁnition of biomarkers as hubs and bottlenecks connecting to differ-
ent network elements of importance in signal transduction.
• Network simulations and ﬂux analyses to unravel the dynamics and
elasticity of physiological and pathological states and the impact
of interventions.
• Simulations integrating molecular interactions and correlations.
• Computational predictions and actionable knowledge.
This pipeline can be operationalized using models of cellular re-
sponses, organs, systems, or conditions for designing and testing inter-
vention or clinical studies. The initial (tissue-speciﬁc) framework,
describing in molecular detail the processes of transport, metabolism
and signaling in steady state, as well as during challenges with altered
diet, physical activity, fasting, and sleeping may be developed from
model organisms (van Ommen et al., 2009). However, and importantly
for translational human genomics, system thinking and approaches can
also be applied directly to humans in clinical settingswith the additional
concept that determining responses to diet, drugs, treatments, and vac-
cines based on genetic makeup and molecular phenotyping will be an
iterative process (Kaput, 2008; Zazzu et al., 2013).
6. Perspectives
Model systems continue to play an important role for understanding
disease and health processes since the types of experiments, control or
knowledge of genetic variation, ability to regulate environmental vari-
ables, and accessibility to a range of tissues are greater than in human
studies. However, the best model for developing an understanding of
health and disease is the human. The paradigm shift (Kuhn, 1962) nec-
essary in translational human health research is the recognition of the
necessity to capture the complexity and dynamics of biological process-
es using omics in response to changing environmental exposures rather
than trying to reduce this complexity to artiﬁcial levels that may be less
meaningful for a real-life situation.
Translational genomics should therefore investigate how genomic
and epigenomic individuality predisposes to health and disease and
how an individual's genome expresses itself at different omic levels(proteomics, metabonomics, lipidomics) in response to environment,
including e.g. nutrition and physical activity. This more comprehensive
strategy requires extensive molecular phenotyping of humans which
includes analysis of environmental, genomic, microbiological and epi-
demiological factors (Kaput and Morine, 2012; Kaput et al., 2014;
Kussmann et al., 2013) and expansion of computational methods for
data analysis:
1. A system approach to human health implies rethinking in vitro and
in vivomodelswith regard to their translatability into humanpheno-
types: natural human cell models and panels of rodent strains should
complement cancer cell lines and single rodent strains (Inselman
et al., 2011).
2. Classical case/control designs of human clinical/nutritional interven-
tion studies should be complemented by crossover, longitudinal
studies, in which every subject is its own case and control (Kaput
and Morine, 2012).
3. Human clinical study subjects should not only be assessed at homeo-
stasis, e.g. fasting when the metabolic system is “at rest”, but also
during a challenge to and restoration of homeostasis. Such safe chal-
lenges can be nutritional, physical, or cognitive in nature (van
Ommen et al., 2009).
4. Classical genomic studies have been technology-driven rather
than technology-rooted: the incentive to measure omic proﬁles of
human subjects in clinical studies has often stemmed from recent
developments and availability of genetic, epigenetic and omic
platforms (Kussmann and Van Bladeren, 2011). This needs to be
complemented by more comprehensive systems biology-based in-
vestigations deploying a multitude of omic platforms in an integrat-
ed fashion.
5. While comprehensive and quantitative omics are rapidly progressing
in termsof data generation, quantitative capture andmonitoring of the
human environment, including diet, lifestyle, and socio-economic
status have lagged behind. This limitation is now being addressed
by more attractive and precise image-based consumer/research
interfaces.
6. The bottleneck in knowledge generation has moved from the acqui-
sition to processing, visualization and interpretation of the data. This
requires innovative tools and methods including new ways of statis-
tical treatment and biological network analysis.
In addition to capturing population-representative proﬁles, the era
of personal (gen)omics is now emerging. Ultimately, the omics sciences
form the analytical basis for an integrated, systematic and quantitative
understanding of how a living system functions, be it an organelle,
cell, organ, whole organism or even an entire ecosystem. This capability
of simulating (“modeling”) a living system's behavior and predicting its
responses towards external stimuli is the art of systems biology, which
roots in a data-driven omics information culture. Translational research,
and in particular translational genomics research expands pure funda-
mental science to augment the understanding of the physiological re-
sponse of an individual to changing environments. This knowledge
can form the basis to generate new solutions that can be applied in
real time to assess, mitigate, improve, or delay disease symptoms and
to maintain health.
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